Trial Profile

A prospective, single-arm clinical study on Tislelizumab in combination with albumin-bound paclitaxel followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer (TREND)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anthracyclines (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
Indications Breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TREND

06 Jun 2023 Interim Results (n=43) assessing safety and efficacy of of tislelizumab in combination with nab-P and EC (nab-P-EC) in neoadjuvant therapy of TNBC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
03 Dec 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com